ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 2 مورد

Major placebo-controlled randomized trials of treatment of pregnant patients with magnesium sulfate for neuroprotection of offspring

Major placebo-controlled randomized trials of treatment of pregnant patients with magnesium sulfate for neuroprotection of offspring
Trial Number of subjects Gestational age at randomization (weeks) Magnesium sulfate dose Death Cerebral palsy Composite outcome Other outcomes
ACTOMgSO4 1062 <30 4 g loading dose followed by 1 g/hour for maximum of 24 hours Total pediatric mortality:
  • 13.8 versus 17.1%
  • RR 0.83
  • 95% CI 0.64-1.09
 Cerebral palsy:
  • 6.8 versus 8.2%
  • RR 0.83
  • 95% CI 0.54-1.27
 Death or cerebral palsy:
  • 19.8 versus 24.0%
  • RR 0.83
  • 95% CI 0.66-1.03
 Substantial gross motor dysfunction:
  • 3.4 versus 6.6%
  • RR 0.51
  • 95% CI 0.29-0.91

Death or substantial gross motor dysfunction:

  • 17.0 versus 22.7%
  • RR 0.75
  • 95% CI 0.59-0.96
BEAM 2241 24 to 31 6 g loading dose followed by 2 g/hour for maximum of 12 hours Death:
  • 9.5 versus 8.5%
  • RR 1.12
  • 95% CI 0.85-1.47
 Moderate to severe cerebral palsy:
  • 1.9 versus 3.5%
  • RR 0.55
  • 95% CI 0.32-0.95*
 Stillbirth or infant death by one year of corrected age or moderate or severe cerebral palsy at or beyond two years of corrected age:
  • 11.3 versus 11.7%
  • RR 0.97
  • 95% CI 0.77-1.23
  
PREMAG 573 <33 4 g loading dose, no maintenance dose     Cerebral palsy or death:
  • OR 0.65
  • 95% CI 0.42-1.03

Severe motor dysfunction or death:

  • OR 0.62
  • 95% CI 0.41-0.93
  
MAGENTA 1433

30 to <32

32 to <34		 4 g loading dose, no maintenance dose Death of liveborn infant before hospital discharge:
  • 0.6 versus 0.5%
  • RR 1.50
  • 95% CI 0.58-3.86
 Cerebral palsy:
  • 1.6 versus 1.7%
  • RR 0.98
  • 95% CI 0.43-2.23
 Death or cerebral palsy:
  • 3.3 versus 2.7%
  • RR 1.19
  • 95% CI 0.65-2.18
  
Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm 560 24 to <32 5 g loading dose followed by 1 g/hour maintenance dose until delivery or a for 24 hours if delivery has not occurred Death:
  • Fetal to <28 days: 4.4 versus 5.0% (aOR 0.82, 95% CI 0.38-1.76)
  • ≥28 days: 0.9 versus 1.2% (aOR 0.68, 95% CI 0.15-3.14)
  • Total: 6.4 versus 7.1% (aOR 0.85, 95% CI 0.45-1.60)
 Cerebral palsy:
  • Moderate to severe: 2 versus 3.3% (aOR 0.61, 95% CI 0.23-1.65)
  • Mild: 1.5 versus 2.4% (aOR 0.60, 95% CI 0.20-1.86)
  • Any: 3.5 versus 5.6% (aOR 0.60, 95% CI 0.28-1.27)
  • Moderate to severe cerebral palsy (assessed at 18 months of corrected age or older) or total deaths (assessed at 18 months of corrected age): 8.5 versus 10.4% (aOR 0.77, 95% CI 0.45-1.32)
  • Any cerebral palsy (assessed at 18 months of corrected age or older) or total deaths (assessed at 18 months of corrected age): 9.9 versus 12.7% (aOR 0.73, 95% CI 0.44-1.20)
  

ACTOMgSO4: Australasian Collaborative Trial of Magnesium Sulphate; aOR: adjusted odds ratio; BEAM: Beneficial Effects of Antenatal Magnesium Sulfate; MAGENTA: Magnesium Sulphate at 30 to 34 Weeks' Gestational Age; OR: odds ratio; RR: relative risk.

* When evaluated in terms of gestational age at randomization (<28 weeks versus ≥28 weeks), only infants of pregnancies randomized at <28 weeks had a significant reduction in moderate or severe cerebral palsy.
Graphic 108643 Version 4.0